Bioinfra Co Ltd
199730
Company Profile
Business description
Bioinfra Co Ltd includes bioequivalence testing of generic drugs, Phase 1 clinical trials for improved new drugs, regulatory approval clinical trials, immunoassays, and pharmaceutical quality testing.
Contact
120 Heungdeokjungang-ro
4th and 5th Floors
Giheung-gu, Yongin-si
Gyeonggi-do16950
KORT: +82 316272800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
138
Stocks News & Analysis
stocks
Earnings up but shares overvalued for ASX gold miner
Higher gold prices are making a difference to the bottom line but investors overly optimistic.
stocks
Alphabet: Anthropic deal and Gemini momentum stand to deliver; Fair Value up 27%
We see faster cloud growth and improved longer-term profitability for Alphabet.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,351.90 | 4.90 | -0.05% |
| CAC 40 | 8,225.24 | 0.39 | -0.00% |
| DAX 40 | 24,290.26 | 50.37 | 0.21% |
| Dow JONES (US) | 47,207.12 | 472.51 | 1.01% |
| FTSE 100 | 9,643.42 | 2.20 | -0.02% |
| HKSE | 26,433.70 | 273.55 | 1.05% |
| NASDAQ | 23,204.87 | 263.07 | 1.15% |
| Nikkei 225 | 50,512.32 | 1,212.67 | 2.46% |
| NZX 50 Index | 13,391.59 | 14.49 | 0.11% |
| S&P 500 | 6,791.69 | 53.25 | 0.79% |
| S&P/ASX 200 | 9,055.60 | 2.20 | -0.02% |
| SSE Composite Index | 3,996.94 | 46.63 | 1.18% |